POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (RACA) is a radiopharmaceutical company that entered public markets through a SPAC merger, combining with GX Acquisition Corp. II, a blank-check vehicle sponsored by GX Capital that completed its IPO in 2020. The combined company focuses on the development and commercialization of radioligand therapies targeting cancer. POINT Biopharma filed this Form 8-K on October 3, 2023, during a period in which the company announced a definitive agreement to be acquired by Eli Lilly and Company, effectively closing its chapter as a standalone public entity following the de-SPAC transaction. For comprehensive filing histories, sponsor profiles, and deal-level analytics across the SPAC universe, create a free account at SpacDesk.